RIPK2 and prostate carcinoma: Our study found that RIPK2 expression was elevated in 22RV1/DTX, C4-2/DTX, PC-3/DTX, and DU145/DTX prostate cancer cells, and silencing RIPK2 expression increased cell sensitivity to DTX.